Distribution of transient receptor potential vanilloid-1 channels in gastrointestinal tract of patients with morbid obesity.
Capsaicin
Immunohistochemistry
Morbid obesity
Obesity
Transient receptor potential channels
Transient receptor potential vanilloid 1
Transient receptor potential vanilloid cation channels
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
07 Jan 2022
07 Jan 2022
Historique:
received:
21
04
2021
revised:
25
06
2021
accepted:
23
11
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
25
1
2022
Statut:
ppublish
Résumé
Transient receptor potential vanilloid-1 (TRPV1), a nonselective cation channel, is activated by capsaicin, a pungent ingredient of hot pepper. Previous studies have suggested a link between obesity and capsaicin-associated pathways, and activation of TRPV1 may provide an alternative approach for obesity treatment. However, data on the TRPV1 distribution in human gastric mucosa are limited, and the degree of TRPV1 distribution in the gastric and duodenal mucosal cells of obese people in comparison with normal-weight individuals is unknown. To clarify gastric and duodenal mucosal expression of TRPV1 in humans and compare TRPV1 expression in obese and healthy individuals. Forty-six patients with a body mass index (BMI) of > 40 kg/m TRPV1 expression was higher in the stomach than in the duodenum and was predominantly found in parietal and chief cells of the fundus and mucous and foveolar cells of the antrum. Unlike foveolar cells in the antrum, TRPV1 was relatively low in foveolar cells in the fundus (4.92 ± 0.49 The expression of TRPV1 is unchanged in the gastroduodenal mucosa of morbidly obese patients demonstrating that drugs targeting TRPV1 may be effective in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Transient receptor potential vanilloid-1 (TRPV1), a nonselective cation channel, is activated by capsaicin, a pungent ingredient of hot pepper. Previous studies have suggested a link between obesity and capsaicin-associated pathways, and activation of TRPV1 may provide an alternative approach for obesity treatment. However, data on the TRPV1 distribution in human gastric mucosa are limited, and the degree of TRPV1 distribution in the gastric and duodenal mucosal cells of obese people in comparison with normal-weight individuals is unknown.
AIM
OBJECTIVE
To clarify gastric and duodenal mucosal expression of TRPV1 in humans and compare TRPV1 expression in obese and healthy individuals.
METHODS
METHODS
Forty-six patients with a body mass index (BMI) of > 40 kg/m
RESULTS
RESULTS
TRPV1 expression was higher in the stomach than in the duodenum and was predominantly found in parietal and chief cells of the fundus and mucous and foveolar cells of the antrum. Unlike foveolar cells in the antrum, TRPV1 was relatively low in foveolar cells in the fundus (4.92 ± 0.49
CONCLUSION
CONCLUSIONS
The expression of TRPV1 is unchanged in the gastroduodenal mucosa of morbidly obese patients demonstrating that drugs targeting TRPV1 may be effective in these patients.
Identifiants
pubmed: 35071508
doi: 10.12998/wjcc.v10.i1.79
pmc: PMC8727248
doi:
Types de publication
Journal Article
Langues
eng
Pagination
79-90Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: There is no conflict of interest.
Références
Mol Biol Rep. 2012 Jul;39(7):7583-9
pubmed: 22327653
Am J Gastroenterol. 2013 Mar;108(3):331-45; quiz 346
pubmed: 23381016
Wideochir Inne Tech Maloinwazyjne. 2014 Dec;9(4):554-61
pubmed: 25561993
Br J Nutr. 1998 Dec;80(6):503-10
pubmed: 10211048
Histochem Cell Biol. 2005 Jul;124(1):61-8
pubmed: 16041554
Pharmacol Res. 2000 Mar;41(3):265-81
pubmed: 10675278
Eur J Neurosci. 2007 Jan;25(1):213-23
pubmed: 17241282
Dig Dis Sci. 1998 Jun;43(6):1165-71
pubmed: 9635602
Ann Nutr Metab. 2017;70(4):277-285
pubmed: 28595182
Br J Pharmacol. 2016 Aug;173(15):2369-89
pubmed: 27174467
Biosci Rep. 2017 May 11;37(3):
pubmed: 28424369
Nutr Res. 2018 Apr;52:71-79
pubmed: 29530622
J Nutr Sci Vitaminol (Tokyo). 1995 Dec;41(6):647-56
pubmed: 8926537
Nat Rev Drug Discov. 2012 Sep;11(9):675-91
pubmed: 22858652
Anat Cell Biol. 2012 Mar;45(1):1-16
pubmed: 22536547
Neurogastroenterol Motil. 2007 May;19(5):333-41
pubmed: 17509015
J Neurophysiol. 2019 Jan 1;121(1):140-151
pubmed: 30461371
Circ Res. 2007 Apr 13;100(7):1063-70
pubmed: 17347480
Am J Clin Nutr. 2009 Jan;89(1):45-50
pubmed: 19056576
Scand J Gastroenterol. 2004 Apr;39(4):303-12
pubmed: 15125461
Food Funct. 2020 Sep 23;11(9):7356-7370
pubmed: 32820787
Dig Dis Sci. 2009 Mar;54(3):491-8
pubmed: 18668366
Drug Saf. 2008;31(1):53-65
pubmed: 18095746
Biochem Biophys Res Commun. 2005 Jul 8;332(3):756-62
pubmed: 15907794
Life Sci. 2008 Jul 4;83(1-2):1-5
pubmed: 18541272
Obes Surg. 2007 Oct;17(10):1399-407
pubmed: 18098402
Adv Nutr. 2019 Jan 1;10(suppl_1):S4-S9
pubmed: 30721956
J Agric Food Chem. 2007 Mar 7;55(5):1730-6
pubmed: 17295509
PLoS One. 2013 Jul 02;8(7):e67786
pubmed: 23844093
J Neuroendocrinol. 2018 Nov;30(11):e12643
pubmed: 30203877
JAMA. 2014 Jan 1;311(1):74-86
pubmed: 24231879
Obes Surg. 2017 Apr;27(4):1037-1046
pubmed: 27900560
J Sleep Disord Ther. 2017 Mar;6(1):
pubmed: 28638745
Appetite. 2014 Jun;77:44-9
pubmed: 24630935
Science. 1986 Feb 7;231(4738):609-11
pubmed: 3511527
Gastrointest Endosc Clin N Am. 2017 Apr;27(2):191-211
pubmed: 28292400
Gastroenterology. 1996 Apr;110(4):1043-52
pubmed: 8612992
Toxicol Appl Pharmacol. 1984 Mar 15;72(3):449-56
pubmed: 6710495
Int Heart J. 2016 Jul 27;57(4):441-8
pubmed: 27396556
Neurosci Lett. 2001 Aug 17;309(1):33-6
pubmed: 11489540
Drugs Context. 2015 Jul 09;4:212283
pubmed: 26213556
Cell Res. 2012 Mar;22(3):551-64
pubmed: 22184011
Gastroenterology. 2002 Dec;123(6):1904-11
pubmed: 12454847
Obes Rev. 2017 May;18(5):581-593
pubmed: 28273680
Eur J Pharmacol. 2001 Dec 7;432(2-3):203-10
pubmed: 11740957
Cell Calcium. 2005 Sep-Oct;38(3-4):233-52
pubmed: 16098585